docetaxel + oxaliplatin + leucovorin + fluorouracil + treprizumab + S-1

This is a multi-agent combination therapy containing **docetaxel**, **oxaliplatin**, **leucovorin**, **fluorouracil**, **treprizumab**, and **S-1**. - **Docetaxel** is a taxane-class chemotherapy that promotes microtubule assembly and inhibits depolymerization, disrupting mitosis. - **Oxaliplatin** is a platinum-based chemotherapy that forms DNA crosslinks, inhibiting DNA replication and transcription. - **Leucovorin** (folinic acid) enhances the cytotoxicity of fluorouracil by stabilizing its binding to thymidylate synthase[7]. - **Fluorouracil (5-FU)** is a pyrimidine antimetabolite that inhibits thymidylate synthase, leading to DNA synthesis inhibition[7]. - **Treprizumab** is a monoclonal antibody targeting PD-1, acting as an immune checkpoint inhibitor (based on the "-prizumab" naming convention for anti-PD-1 antibodies, specific literature on treprizumab is limited; this inference is based on standard drug-naming conventions and clinical trial databases). - **S-1** is an oral prodrug formulation combining tegafur (a 5-FU prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (to reduce GI toxicity), designed to enhance the therapeutic index of fluorouracil[2][8]. This regimen combines multiple chemotherapeutic agents with different mechanisms of action and an immune checkpoint inhibitor to maximize anti-tumor efficacy, most likely in gastrointestinal cancers (notably gastric or colorectal cancer) given the typical use of these agents[2][6][8].